

ANAGENICS

ASX ANNOUNCEMENT

ANAGENICS LIMITED (ASX: AN1) – H1 FY24 Results and Corporate Update

- Release of H1 FY24 results
- Acceleration of cost base reduction post completion of placement capital raise

SYDNEY, TUESDAY 27 FEBRUARY 2024

Release H1 FY24 results

The Company announced its audited financial results for H1 FY24:

- Total revenue and other income from continuing operations H1 FY24 \$6.3M vs. H1 FY23 \$5.6M, improved by 13.6%
- “Underlying EBITDA”¹ loss for the Group, normalised for one-off and abnormal items, totalled \$1.1M vs. FY23 H1: \$0.5M loss
- Full benefits of business restructuring and integration will commence from Q4 FY24 and are targeted to deliver cash flow positive trading prior to June 30, 2024.

Accelerated Cost Base Reduction and BLC Strategic Review

As previously announced, Anagenics has been reducing its cost base through organisational structure changes. The business has further accelerated these cost reduction measures to deliver cash flow positive trading as a priority, including potential monetisation strategies for non-core assets. In conjunction the board of directors have paused Directors fees to support these efforts

Anagenics’ independent director, Karen Matthews, has taken up a strategic business transformation consulting role to review the BLC Cosmetics business and assist with its restructure. Karen has significant business transformation and beauty industry experience including as CEO of Ella Bache. Karen's role is initially for a one-month period and will receive a fixed consulting fee of \$20,000 + GST.

Further details of the cost reduction measures and BLC strategy reset will be provided upon completion of the review.

Approved for release by the Board of Directors.

Scott Greasley
CEO
+61 412 308 263
info@anagenics.com

Anagenics Limited (ASX: AN1)

¹ Underlying EBITDA is calculated as net profit/(loss) before interest, income tax, depreciation and amortisation, foreign exchange gains/(loss), one off business restructuring costs and other large abnormal items incurred in the period. It is considered the best measure of the Group’s true financial performance. For a detailed reconciliation between net loss after tax to underlying EBITDA please refer to the Anagenics Limited Interim Report – 31 December 2023.

ANAGENICS

Anagenics is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products. For further information, please see www.anagenics.com.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Anagenics to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as, amongst other, the availability of resources, regulatory environment, the results of marketing and sales activities and competition.